Systematic and integrated analysis of tRNA-derived small RNAs reveals novel potential pathogenesis targets of sarcoidosis

Min Zhao, Chang Fu Tian, Xin Di, Xin Jin, Shan Cong, Yingshu Cao, Ke WangResearch Square 2022 · DOI

This research paper, recently published by a team at Jilin University, explores the molecular landscape of sarcoidosis through the lens of tRNA-derived small RNAs (tsRNAs). By combining deep sequencing with clinical data and network biology, the authors identify specific RNA fragments that could serve as both diagnostic biomarkers and therapeutic targets for this complex inflammatory disease.

TL;DR

Researchers have identified a specific signature of tRNA-derived small RNAs (tsRNAs) in the serum of sarcoidosis patients that correlates with disease severity and organ involvement. These fragments, particularly tiRNA-Glu-TTC-001, tiRNA-Lys-CTT-003, and tRF-Ser-TGA-007, appear to regulate critical immune pathways (like cAMP and FoxO), offering a new frontier for non-invasive diagnosis and targeted treatment.

What Problem Does This Paper Address?

Sarcoidosis is a multisystem disease characterized by the formation of non-caseating granulomas (clumps of inflammatory cells). Its exact cause remains a "black box" in medicine. Current protein-based biomarkers like ACE (angiotensin-converting enzyme) lack sufficient sensitivity and specificity for reliable clinical use.

The authors address two major gaps:

  1. The Diagnostic Gap: The need for stable, non-invasive serum biomarkers to identify the disease and monitor its progression.
  2. The Mechanistic Gap: Understanding the regulatory role of non-coding RNAs—specifically tsRNAs—in the immune dysfunction that drives sarcoidosis.

Methods

The study employed a multi-stage "integrated" approach:

  • Discovery: High-throughput small RNA sequencing was performed on serum from a small "development group" (3 patients vs. 3 controls) to identify differentially expressed tsRNAs.
  • Validation: The most promising candidates were validated using qRT-PCR in a larger "validation group" (22 patients vs. 18 controls).
  • Clinical Correlation: The researchers used statistical models to see if tsRNA levels correlated with patient age, blood calcium levels, and the number of affected organ systems.
  • Bioinformatics Pipeline: They used algorithms (TargetScan and miRDB) to predict mRNA targets of these tsRNAs and performed Gene Ontology (GO) and KEGG pathway enrichment analyses.
  • Network Analysis: Using Cytoscape and the cytoHubba plugin, they identified "hub genes"—the most highly connected and likely influential genes within the predicted regulatory networks.

Datasets

  • Primary Sequencing Data: Newly generated small RNA-seq data from serum samples (deposited in the Gene Expression Omnibus under accession no. GSE198490).
  • External Validation Dataset: The authors used the GSE19314 dataset from NCBI-GEO (containing blood samples from 37 sarcoidosis patients and 20 healthy individuals) to verify the expression levels of their identified hub genes.

Key Insights and Ideas

  • tsRNAs as miRNA-like Regulators: The paper reinforces the idea that tsRNAs aren't just "degradation junk" from protein synthesis. They function similarly to microRNAs, binding to and silencing specific messenger RNAs (mRNAs) to control gene expression.
  • The cAMP Connection: A major finding was the enrichment of targets in the cAMP signaling pathway. cAMP is a critical regulator of the Th17/Treg immune balance; its dysregulation is a known hallmark of sarcoidosis.
  • Clinical Signatures:
    • tiRNA-Glu-TTC-001 showed a strong negative correlation with age ($r = -0.911$), suggesting its role might change as the immune system matures or senesces.
  • tRF-Ser-TGA-007 correlated positively with blood calcium levels, a key clinical indicator of sarcoidosis activity.
  • Novel Hub Genes: The study identified several hub genes, including APP (Amyloid Precursor Protein) and PRKACB, as potential downstream targets. While APP is famously linked to Alzheimer’s, this study suggests it may play a role in immune-driven inflammation in sarcoidosis.

Key Results

  • Differential Expression: 13 tsRNAs were significantly dysregulated (4 upregulated, 9 downregulated).
  • Top Biomarkers: Three specific fragments were confirmed as highly accurate diagnostic markers via ROC (Receiver Operating Characteristic) analysis:
  • tRF-Ser-TGA-007: AUC of 0.808
    • tiRNA-Lys-CTT-003: AUC of 0.765
    • tiRNA-Glu-TTC-001: AUC of 0.705
  • Targeting: The analysis predicted that these three tsRNAs collectively target hundreds of mRNAs, with 96 targets being shared across multiple prediction platforms.

Limitations and Future Work

  • Sample Size: The initial sequencing was performed on a very small group ($n=3$ per group), which may miss lower-abundance fragments.
  • Lack of Functional Verification: The study is primarily computational and observational. The authors acknowledge that "wet lab" experiments (e.g., knocking down these tsRNAs in cell cultures) are needed to prove they actually cause the changes in the predicted hub genes.
  • Cross-Disease Specificity: While these tsRNAs are different in sarcoidosis vs. healthy controls, further research is needed to ensure they aren't also dysregulated in other similar inflammatory diseases (like tuberculosis).
  • Longitudinal Data: The study does not track how these RNA levels change over time as a patient responds to treatment (e.g., steroids).

Summary updated

Abstract

<title>Abstract</title> The pathogenesis of sarcoidosis, which involves several systems, is unclear, and its pathological type is non-caseating epithelioid granulomas. tRNA-derived small RNA (tsRNA) is a novel class of short non-coding RNAs with potential regulatory functions. However, whether tsRNA contributes to sarcoidosis pathogenesis remains unclear. Deep sequencing technology was used to identify alterations in tsRNA expression profiles between patients with sarcoidosis and healthy controls. A total of 360 tsRNAs were identified for exact matches. Among them, the expression of three tRNAs (tiRNA-Glu-TTC-001, tiRNA-Lys-CTT-003, and tRF-Ser-TGA-007) was markedly regulated in sarcoidosis and validated by quantitative real-time polymerase chain reaction. The expression of various tsRNAs was significantly correlated with age, the number of affected systems, and calcium levels in the blood. Additionally, target prediction and bioinformatics analyses revealed that these tsRNAs may play roles in chemokine, cAMP, cGMP-PKG, retrograde endorphin, and FoxO signalling pathways. The Cytoscape software was used for visual analysis to obtain 10 hub genes of each target tsRNA. Among the hub genes, <italic>APP</italic> , <italic>PRKACB</italic> , <italic>ARRB2</italic> , and <italic>NR5A1</italic> finding may participate in the occurrence and development of sarcoidosis through immune inflammation. This study provides novel insights to explore tsRNA as a novel and efficacious pathogenic target of sarcoidosis.
BibTeX
@inproceedings{zhao2022systematic,
  author = {Min Zhao and Chang Fu Tian and Xin Di and Xin Jin and Shan Cong and Yingshu Cao and Ke Wang},
  title = {{Systematic and integrated analysis of tRNA-derived small RNAs reveals novel potential pathogenesis targets of sarcoidosis}},
  booktitle = {Research Square},
  year = {2022},
  doi = {10.21203/rs.3.rs-1230171/v1},
}
Figure